Literature DB >> 26609053

Aberrant Activation of Notch Signaling Inhibits PROX1 Activity to Enhance the Malignant Behavior of Thyroid Cancer Cells.

Dongwon Choi1, Swapnika Ramu1, Eunkyung Park1, Eunson Jung1, Sara Yang1, Wonhyeuk Jung1, Inho Choi2, Sunju Lee1, Kyu Eui Kim1, Young Jin Seong1, Mingu Hong1, George Daghlian1, Daniel Kim1, Eugene Shin1, Jung In Seo1, Vicken Khatchadourian1, Mengchen Zou3, Wei Li3, Roger De Filippo4, Paul Kokorowski4, Andy Chang4, Steve Kim4, Ana Bertoni5, Tania Weber Furlanetto6, Sung Shin7, Meng Li8, Yibu Chen8, Alex Wong1, Chester Koh9, Jan Geliebter10, Young-Kwon Hong11.   

Abstract

Papillary thyroid cancer (PTC) is one of the most common endocrine malignancies associated with significant morbidity and mortality. Although multiple studies have contributed to a better understanding of the genetic alterations underlying this frequently arising disease, the downstream molecular effectors that impact PTC pathogenesis remain to be further defined. Here, we report that the regulator of cell fate specification, PROX1, becomes inactivated in PTC through mRNA downregulation and cytoplasmic mislocalization. Expression studies in clinical specimens revealed that aberrantly activated NOTCH signaling promoted PROX1 downregulation and that cytoplasmic mislocalization significantly altered PROX1 protein stability. Importantly, restoration of PROX1 activity in thyroid carcinoma cells revealed that PROX1 not only enhanced Wnt/β-catenin signaling but also regulated several genes known to be associated with PTC, including thyroid cancer protein (TC)-1, SERPINA1, and FABP4. Furthermore, PROX1 reexpression suppressed the malignant phenotypes of thyroid carcinoma cells, such as proliferation, motility, adhesion, invasion, anchorage-independent growth, and polyploidy. Moreover, animal xenograft studies demonstrated that restoration of PROX1 severely impeded tumor formation and suppressed the invasiveness and the nuclear/cytoplasmic ratio of PTC cells. Taken together, our findings demonstrate that NOTCH-induced PROX1 inactivation significantly promotes the malignant behavior of thyroid carcinoma and suggest that PROX1 reactivation may represent a potential therapeutic strategy to attenuate disease progression. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26609053      PMCID: PMC4738160          DOI: 10.1158/0008-5472.CAN-15-1199

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  9-cis retinoic acid promotes lymphangiogenesis and enhances lymphatic vessel regeneration: therapeutic implications of 9-cis retinoic acid for secondary lymphedema.

Authors:  Inho Choi; Sunju Lee; Hee Kyoung Chung; Yong Suk Lee; Kyu Eui Kim; Dongwon Choi; Eun Kyung Park; Dongyun Yang; Tatiana Ecoiffier; John Monahan; Wen Chen; Berenice Aguilar; Ha Neul Lee; Jaehyuk Yoo; Chester J Koh; Lu Chen; Alex K Wong; Young-Kwon Hong
Journal:  Circulation       Date:  2012-01-24       Impact factor: 29.690

2.  The role of microRNA genes in papillary thyroid carcinoma.

Authors:  Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

3.  PROX1 expression in gastric cancer: from hypothesis to evidence.

Authors:  Oana Taban; Anca Maria Cimpean; Marius Raica; Sorin Olariu
Journal:  Anticancer Res       Date:  2014-07       Impact factor: 2.480

4.  Notch1 receptor as a marker of lymph node metastases in papillary thyroid cancer.

Authors:  Hyung Seok Park; Chan-Kwon Jung; Sung Hak Lee; Byung Joo Chae; Dong Jun Lim; Woo Chan Park; Byung Joo Song; Jeong Soo Kim; Sang Seol Jung; Ja-Seong Bae
Journal:  Cancer Sci       Date:  2012-01-16       Impact factor: 6.716

5.  Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion.

Authors:  Vasily Vasko; Allan V Espinosa; William Scouten; Huiling He; Herbert Auer; Sandya Liyanarachchi; Alexander Larin; Victoria Savchenko; Gary L Francis; Albert de la Chapelle; Motoyasu Saji; Matthew D Ringel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-12       Impact factor: 11.205

6.  Ontology-based meta-analysis of global collections of high-throughput public data.

Authors:  Ilya Kupershmidt; Qiaojuan Jane Su; Anoop Grewal; Suman Sundaresh; Inbal Halperin; James Flynn; Mamatha Shekar; Helen Wang; Jenny Park; Wenwu Cui; Gregory D Wall; Robert Wisotzkey; Satnam Alag; Saeid Akhtari; Mostafa Ronaghi
Journal:  PLoS One       Date:  2010-09-29       Impact factor: 3.240

7.  Effects of denaturation with HCl on the immunological staining of bromodeoxyuridine incorporated into DNA.

Authors:  K Sasaki; S Adachi; T Yamamoto; T Murakami; K Tanaka; M Takahashi
Journal:  Cytometry       Date:  1988-01

8.  Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells.

Authors:  X Cao; J Geradts; M W Dewhirst; H-W Lo
Journal:  Oncogene       Date:  2011-06-13       Impact factor: 9.867

9.  Expression and prognostic value of transcription factor PROX1 in colorectal cancer.

Authors:  M Skog; P Bono; M Lundin; J Lundin; J Louhimo; N Linder; T V Petrova; L C Andersson; H Joensuu; K Alitalo; C H Haglund
Journal:  Br J Cancer       Date:  2011-10-04       Impact factor: 7.640

10.  Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas.

Authors:  J M Pita; A Banito; B M Cavaco; V Leite
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more
  21 in total

1.  Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer.

Authors:  Emiko Niiro; Sachiko Morioka; Kana Iwai; Yuki Yamada; Kenji Ogawa; Naoki Kawahara; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2018-01-17

2.  Abnormal activation of notch 1 signaling causes apoptosis resistance in cervical cancer.

Authors:  Lu Yu; Wei Li
Journal:  Int J Clin Exp Pathol       Date:  2022-01-15

3.  SLC8A1 antisense RNA 1 suppresses papillary thyroid cancer malignant progression via the FUS RNA binding protein (FUS)/NUMB like endocytic adaptor protein (Numbl) axis.

Authors:  Yunchao Xin; Xiaoling Shang; Xiaoran Sun; Guogang Xu; Yachao Liu; Yanbin Liu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

4.  The Lymphatic Cell Environment Promotes Kaposi Sarcoma Development by Prox1-Enhanced Productive Lytic Replication of Kaposi Sarcoma Herpes Virus.

Authors:  Dongwon Choi; Eunkyung Park; Kyu Eui Kim; Eunson Jung; Young Jin Seong; Luping Zhao; Shrimika Madhavan; George Daghlian; Hansuh H Lee; Patill T Daghlian; Saren Daghlian; Khoa Bui; Chester J Koh; Alex K Wong; Il-Taeg Cho; Young-Kwon Hong
Journal:  Cancer Res       Date:  2020-06-09       Impact factor: 12.701

Review 5.  Notch Signaling in Thyroid Cancer.

Authors:  Rachael Guenter; Zeelu Patel; Herbert Chen
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.

Authors:  Kapo Saukkonen; Jaana Hagström; Harri Mustonen; Anne Juuti; Stig Nordling; Pauliina Kallio; Kari Alitalo; Hanna Seppänen; Caj Haglund
Journal:  BMC Cancer       Date:  2016-07-13       Impact factor: 4.430

7.  Overexpression of NOTCH-regulated Ankyrin Repeat Protein is associated with papillary thyroid carcinoma progression.

Authors:  Mingdi Zhang; Yiyu Qin; Bin Zuo; Wei Gong; Shenglai Zhang; Yurong Gong; Zhiwei Quan; Bingfeng Chu
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

8.  CXCL12 methylation-mediated epigenetic regulation of gene expression in papillary thyroid carcinoma.

Authors:  Sijia Zhang; Yihan Wang; Meijun Chen; Lulu Sun; Jun Han; V Kazakova Elena; Hong Qiao
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

9.  The role of prospero homeobox 1 (PROX1) expression in follicular thyroid carcinoma cells.

Authors:  Magdalena Rudzinska; Joanna K Ledwon; Damian Gawel; Justyna Sikorska; Barbara Czarnocka
Journal:  Oncotarget       Date:  2017-12-12

10.  PROX1 is a transcriptional regulator of MMP14.

Authors:  Silvia Gramolelli; Jianpin Cheng; Ines Martinez-Corral; Markus Vähä-Koskela; Endrit Elbasani; Elisa Kaivanto; Ville Rantanen; Krista Tuohinto; Sampsa Hautaniemi; Mark Bower; Caj Haglund; Kari Alitalo; Taija Mäkinen; Tatiana V Petrova; Kaisa Lehti; Päivi M Ojala
Journal:  Sci Rep       Date:  2018-06-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.